Timolol Maleate Ophthalmic Gel Forming Solution 0.25% + Beta-Adrenergic Blocking Agents (Topical)Major
Concomitant use of two topical beta-adrenergic blocking agents is not recommended.
Source: NLP:timolol maleate ophthalmic gel forming solution
Timolol Maleate Ophthalmic Gel Forming Solution 0.25% Interactions
Brand names: Timolol Maleate Ophthalmic Gel Forming Solution 0.25%, Timolol Maleate Ophthalmic Gel Forming Solution 0.5%
Route: Ophthalmic
Contraindications
CONTRAINDICATIONS Timolol maleate ophthalmic gel forming solution is contraindicated in patients with (1) bronchial asthma; (2) a history of bronchial asthma; (3) severe chronic obstructive pulmonary disease [see WARNINGS ,Obstructive Pulmonary Disease ]; (4) sinus bradycardia; (5) second or third degree atrioventricular block; (6) overt cardiac failure[see WARNINGS , Cardiac Failure ]; (7) cardiogenic shock; or (8) hypersensitivity to any component of this product.
Pregnancy & Breastfeeding
Pregnancy Teratogenic Effects Teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of fetal malformations. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity. There are no adequate and well-controlled studiesin pregnant women.Timolol maleate ophthalmic gel forming solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
11 interactions on record
Caution advised due to possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. Avoid in patients with impaired cardiac function.
Source: NLP:timolol maleate ophthalmic gel forming solution
Injectable epinephrine interaction noted; see Precautions section regarding anaphylaxis management.
Source: NLP:timolol maleate ophthalmic gel forming solution, 0.25%
Potentiated systemic beta-blockade including decreased heart rate and depression has been reported during combined treatment.
Source: NLP:timolol maleate ophthalmic gel forming solution
Close observation recommended due to possible additive effects and production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.
Source: NLP:timolol maleate ophthalmic gel forming solution
Oral beta-adrenergic blocking agents may exacerbate rebound hypertension following clonidine withdrawal; no reports with ophthalmic timolol maleate.
Source: NLP:timolol maleate ophthalmic gel forming solution
Concomitant use may have additive effects in prolonging atrioventricular conduction time.
Source: NLP:timolol maleate ophthalmic gel forming solution
Timolol Maleate Ophthalmic Gel Forming Solution 0.25% + Nonselective Beta-Adrenergic AntagonistsModerate
Concomitant use of two topical beta-adrenergic blocking agents is not recommended. Patients receiving oral beta-blockers with timolol should be observed for additive effects of beta-blockade.
Source: NLP:timolol maleate ophthalmic gel forming solution 0.25%
Timolol Maleate Ophthalmic Gel Forming Solution 0.25% + Oral Beta-Adrenergic Blocking AgentsModerate
Potential additive effects of beta-blockade, both systemic and on intraocular pressure. Observation for additive effects recommended.
Source: NLP:timolol maleate ophthalmic gel forming solution
Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and Timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as Timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. quinidine, SSRIs) and timolol.
Source: FDA drug label - timolol maleate ophthalmic gel forming solution 0.25%
Interaction noted in precautions regarding anaphylaxis.
Source: NLP:timolol maleate ophthalmic gel forming solution